Insider Sell: Cytokinetics
5:14PM ET 5/18/2022 MT NewswiresRobert I Blum, Director, President & CEO, on May 16, 2022, sold 10,000 shares in Cytokinetics (CYTK) for $431,065. Following the Form 4 filing with the...
Quotes Snapshot > CYTK
Cytokinetics Inc CYTK:NASDAQ
Last Price$39.76NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22
Today's Change+0.97(2.50%)
Bid (Size)$39.15 (1)
Ask (Size)$44.87 (3)
Day Low / High$38.03 - 39.85
Volume710.8 K
Read more news Recent News
--Mizuho Securities Lifts Cytokinetics' Price Target to $80 From $54, Citing Aficamten Sales Estimates; Buy Rating Kept
4:34AM ET 5/16/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
-- Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Reports Q1 Revenue $1.1M
4:01PM ET 5/04/2022 MT Newswires...
--Oppenheimer Adjusts Cytokinetics Price Target to $57 From $53, Maintains Outperform Rating
12:28PM ET 4/29/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q1 2022 Results - Earnings Call Transcript
10:15PM ET 5/04/2022 Seeking AlphaCytokinetics: A Brighter Future In Muscle Biology
3:59PM ET 4/11/2022 Seeking AlphaCytokinetics (CYTK) Investor Presentation - Slideshow
1:21PM ET 3/16/2022 Seeking AlphaCytokinetics, Incorporated (CYTK) CEO Robert Blum on Q4 2021 Results - Earnings Call Transcript
9:35AM ET 2/25/2022 Seeking AlphaCompany Profile
Business DescriptionCytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 350 Oyster Point Boulevard South San Francisco, California 94080 |
| Phone | +1.650.624.3000 |
| Number of Employees | 130 |
| Recent SEC Filing | 05/18/2022 8-K |
| President, Chief Executive Officer & Director | Robert I. Blum |
| Vice President-Development Operations | Eric Terhaerdt |
| Chief Financial Officer & Senior Vice President | Ching W. Jaw |
| Executive Vice President-Research & Development | Fady Ibraham Malik |
Company Highlights
| Price Open | $39.23 |
| Previous Close | $38.79 |
| 52 Week Range | $17.72 - 47.90 |
| Market Capitalization | $3.4 B |
| Shares Outstanding | 85.7 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/04/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$3.20 |
| Beta vs. S&P 500 | N/A |
| Revenue | $31.5 M |
| Net Profit Margin | -396.22% |
| Return on Equity | -164.73% |
Analyst Ratings as of 01/31/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |